Across TCGA pan-cancer cohorts, CAPN3 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CAPN3 data layer compared with 26 for mass-spec protein and 8 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CAPN3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CAPN3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.
HNSC and LSCC are the cancer types where CAPN3 mass-spec protein most reproducibly stratifies survival.